2020, Number 2
Relationship between COVID-19 and Hypertension
Language: Spanish
References: 33
Page: 1-11
PDF size: 850.55 Kb.
ABSTRACT
Introduction: The first three months of 2020 have been influenced by the spreading of a pandemic caused by the SARS-coronavirus 2, which causes COVID-19 infection that in some cases is associated with acute respiratory distress syndrome.Objective: To identify the relationship between COVID-19 and hypertension.
Material and Methods: A bibliographic review was carried out using database search engines. In addition, reference literature in Cardiology was used as well as information from official government websites such as WHO/PAHO and other scientific societies.
Development: Coronaviruses enter into target cells through a spike S protein, whose S1 surface unit is coupled to the angiotensin-converting enzyme 2 as a receptor. In the different revised series, the clear relationship between the history of arterial hypertension and the unfavorable evolution is observed in patients with COVID-19. In an extensive literature search, there is no scientific evidence for discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hypertensive patients with COVID-19.
Conclusions: The angiotensin-converting enzyme acts as a SARS-CoV2 receptor. Hypertensive individuals have a less favorable evolution course of the condition caused by this virus. Discontinuation of treatment with angiotensinconverting enzyme inhibitors or angiotensin receptor blockers is not advisable in hypertensive patients with COVID-19.
REFERENCES
Cumulative suspected and confirmed COVID- 19 cases reported by countries and territories in the Americas, as of 23 March 2020 [Internet]. PAHO. 2020 [Citado 23/03/2020]. Disponible en: https://www.paho.org/en/documents/pdfdocument- cumulative-suspected-andconfirmed- COVID-19-cases-reported-countriesand-1
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [Internet]. 2020 Mar 4 [Citado 23/03/2020];181:1-10. Disponible en: https://doi.org/10.1016/j.cell.2020.02.052
James PA, Oparil S, Carter BL, Cushman WC, Dennison Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA [Internet]. 2014 [Citado 23/03/2020];311(5):507-20. Disponible en: https://jamanetwork.com/journals/jama/fullarti cle/1791497
Whelton PK, Carey RM, Aronow WS, Casey Jr DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/ AHA/ AAPA/ ABC/ ACPM/ AGS/ APhA/ ASH/ ASPC/ NMA/ PCNA. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertensionl [Internet]. 2018 Jun [Citado 23/03/2020];71(6):1269-324. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/291333 54
Williams B, Mancia G, Spiering W, Agabiti E, Azizi M, Burnier M, et al. Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Rev Esp Cardiol [Internet]. 2019 [Citado 23/03/2020];72(2):160.e1-e78. Disponible en: https://doi.org/10.1016/j.recesp.10.1016/j.reces p.2018.11.022
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al (ACCOMPLISH Trial Investigators). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med [Internet]. 2008 [Citado 23/03/2020];359(23):2417-28. Disponible en: https://doi.org/10.1056/NEJMoa0806182
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al (LIFE Study Group). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet [Internet]. 2002 [Citado 23/03/2020] ;359(9311):995-1003. Disponible en: https://doi.org/10.1016/S0140- 6736(02)08089-3
Rodríguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguín- Rivera Y, Escalera-Antezana JP, et al (LANCOVID- 19). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis [article in press]. Travel Medicine and Infectious Disease [Internet]. 2020 [Citado 23/03/2020]. Disponible en: https://doi.org/10.1016/j.tmaid.2020.101623.
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory síndrome coronavirus 2 (SARS-CoV-2): Facts and myths [article in press]. J Microbiol Immunol Infec [Internet]. 2020 Mar 4 [Citado 23/03/2020]. Disponible en: https://doi.org/10.1016/j.jmii.2020.02.012
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia inWuhan, China. JAMA Intern Med [Internet]. 2020 Mar 13 [Citado 23/03/2020]. Disponible en: https://doi.org/10.1001/jamainternmed.2020.0 994
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis [article in press]. International Journal of Infectious Diseases [Internet]. 2020 [Citado 23/03/2020]. Disponible en: https://doi.org/10.1016/j.ijid.2020.03.017
Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. European Society of Cardiology. 13 marzo 2020 [Citado 23/03/2020]. Disponible en: https://www.escardio.org/Councils/Council-on- Hypertension-(CHT)/News/position-statementof- the-esc-council-on-hypertension-on-aceinhibitors- and-ang
Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology [Internet]. AHA/HFSA/ACC.17 marzo 2020 [Citado 23/03/2020]. Disponible en: https://newsroom.heart.org/news/patientstaking-ace-i-and-arbs-who-contract-COVID-19-should-continue-treatment-unless-otherwiseadvised-by-their-physician